1. At a Glance – Fire, Fallout & Financial Flatline
Sigachi Industries is currently trading at ₹21.9 with a market cap of ₹831 crore. In the last 3 months alone, the stock has fallen 35.9%. One year? Down 43.2%. The market is not whispering. It is shouting.
Q3 FY26 revenue came in at ₹117 crore, down 15.9% YoY. EBITDA margin collapsed to 4.6%. PAT? A net loss of ₹0.01 crore. Yes, effectively zero profit. EPS for the quarter stands at ₹0.01.
ROCE sits at 15.5%. ROE is 13.5%. Debt to equity is 0.29. Promoters hold 39.7%, but 40.3% of their holding is pledged. Promoter holding also fell by 0.78% last quarter.
Meanwhile, a dust explosion at the Hyderabad plant led to 46 fatalities and operations suspension. Insurance claims of ~₹70 crore are expected. Management says demand is strong. Margins will recover. Expansion is on track.
Investors are asking a simple question: Is this a comeback story or a capital destruction case study in progress?
Let’s investigate.
2. Introduction – From Excipients to Explosions
Sigachi Industries was one of those under-the-radar pharma support stories. Not the glamorous drug maker. Not the blockbuster molecule owner. Instead, the quiet enabler.
They make Microcrystalline Cellulose (MCC) — the boring but essential ingredient that helps tablets stay tablets.
For years, the numbers looked respectable:
- 5-year sales growth: 29%
- 5-year profit growth: 28%
- ROE around 15%
Then Q3 FY26 happened.
A dust explosion at the Hyderabad unit led to 46 confirmed fatalities. Operations suspended. Overheads redistributed. Logistics costs jumped. Customs duty hit margins.
Revenue declined. Margins collapsed. PAT evaporated.
And the stock? It followed.
But here’s the twist. Management says:
- Demand is intact.
- Pricing is stable.
- Capacity expansion continues.
- Insurance money is coming.
So is this just a painful transition quarter? Or the beginning of prolonged operational instability?
Time to open the financial files.
3. Business Model – WTF Do They Even Do?
Let’s simplify.
Sigachi manufactures cellulose-based excipients. That’s pharmaceutical filler material used in tablets.
If
